Officials with the FDA have granted breakthrough therapy designation to trastuzumab deruxtecan (Enhertu, AstraZeneca and Daiichi Sankyo) for the treatment of HER2-mutant metastatic non-small cell lung cancer (NSCLC).
In a video interview with Drug Topics®, Robert Brunault, PharmD, a clinical pharmacy specialist of hematology and oncology at Rhode Island Hospital and Lifespan Cancer Institute, answers questions about how the COVID-19 pandemic affects patients undergoing treatment for cancer.
Overall cancer death rates declined by 29% over a 26-year time period, with the largest single-year drop on record reported from 2016 to 2017.
Approximately 1 in 8 women living in the United States will develop an invasive form of breast cancer at some point in her life
Prostate cancer is the second most common cancer in men after skin cancer.
Various factors can affect a patient’s survival rate.
MCL is an aggressive form of NHL
Why pancreatic cancer death rates are still so high.
A look at one of the most common forms of skin cancer.
Fourth filgrastim biosimilar from Sandoz, expected ASAP.